Access cutting-edge neuroblastoma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access neuroblastoma specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related neuroblastoma treatment provided free
This Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor in pediatric subjects with relapsed or refractory neuroblastoma (NB). The trial will be conducted in two phases: Phase 1 will determine the maximum tolerated dose (MTD) of autologous hALK.CAR T cells using a 3+3 dose escalation design. Phase 2 will be an expansion phase to determine rates of respo
Sponsor: Roberto Chiarle
Check if you qualify for this neuroblastoma clinical trial in Boston, MA
If you're searching for neuroblastoma treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neuroblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.